Trial of a new valve for severe tricuspid regurgitation
Part of Heart & circulation clinical trials.
This trial tests a new device, called the Laplace TTVR System, to replace the tricuspid valve in people whose leaky valve (tricuspid regurgitation) continues to cause symptoms despite medical treatment. It may help if you have severe symptoms and are not a candidate for open-heart surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You still have symptoms from your leaky tricuspid valve even after taking heart medications for at least 30 days.
- Your leaky valve is severe, massive, or torrential (the worst grades) as seen on an echocardiogram.
- You are considered a good candidate for a catheter-based valve replacement by your heart team and a selection committee.
- You agree to return for all follow-up visits after the procedure.
- Your heart anatomy is a match for the Laplace TTVR device.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device that replaces a leaky tricuspid valve (a heart valve) without open-heart surgery. If your tricuspid valve isn't working well and medicines haven't helped enough, this procedure might improve your heart function and symptoms.
This trial tests a new, less invasive valve device (TricValve) for people with severe tricuspid regurgitation who are not good candidates for open-heart surgery. It aims to see if this device can help your heart pump better and improve your symptoms.
This trial tests whether a new minimally invasive valve replacement device (put through a catheter) can improve health in people with severe right-sided tricuspid valve leaking. It’s for patients who are considered too high-risk for standard open-heart tricuspid surgery.
This study tests a new device to fix a leaky tricuspid valve without open-heart surgery. It is for people with severe leakage who are considered too high-risk for traditional surgery.
This trial tests a catheter-based procedure (done through the blood vessels) to repair a severely leaky tricuspid valve. It may help people with symptoms or past hospitalizations from tricuspid valve leakage who are higher-risk for standard surgery.
This study tests a new device to help people with severe tricuspid regurgitation (leaky heart valve) who are at higher risk from surgery. It aims to see if the device can reduce the leak and improve symptoms.
Hear when a new Severe Tricuspid Valve Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.